Vtama in Psoriasis Patients Being Treated With Biologics.

Psoriasis Treatment Center of Central New Jersey

Status and phase: Completed; Phase 4

Conditions: Psoriasis

Treatments: Drug: Tapinarof

Study type: Interventional

Funder types: Other

Identifiers

NCT06103695

PTC10

Details and patient eligibility

About

Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female adult ≥ 18 years of age;
2. Diagnosis of chronic plaque-type
3. Patient with ≥3% BSA
4. Patient has been treated with biologic for a minimum of 24 weeks
5. Able and willing to give written informed consent prior to performance of any study-related procedures.

Exclusion criteria

1. ≤3% BSA
2. Patient not receiving biologic agent, or receiving biologic agent <24weeks

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Vtama

Other group

Description:

open label Vtama

Treatment:

Drug: Tapinarof